Skip to main content

teriflunomide (AUBAGIO®)

 

Status: Recommended with restrictions

Teriflunomide (AUBAGIO®) is recommended as an option for restricted use within NHS Wales.

Teriflunomide (AUBAGIO®) is licensed for the treatment of paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis.

Teriflunomide (AUBAGIO®) is restricted for use for the treatment of active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in paediatric patients aged 10 years and older, who do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

 Final Recommendation: teriflunomide (Aubagio) 4033 (PDF, 305Kb)

Medicine details

Medicine name teriflunomide (AUBAGIO®)
Formulation 7 mg and 14 mg tablet
Reference number 4033
Indication

Treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years

Company Aventis Pharma Ltd
BNF chapter Malignant disease & immunosuppression
Submission type Licence extension for paediatric use
Status Recommended with restrictions
Advice number 1022
AWMSG meeting date 27/04/2022
Date of issue 12/05/2022
NICE guidance

TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis in adults

Commercial arrangement PAS
Follow AWTTC: